BBA
SKYE icon

Baker Bros. Advisors’s Skye Bioscience SKYE Stock Holding History

Baker Bros. Advisors’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$968K Buy
1,575,243
+124,605
+9% +$102K 0.01% 80
2025
Q4 		$1.09M Hold
1,450,638
– – 0.01% 81
2025
Q3 		$5.7M Hold
1,450,638
– – 0.04% 71
2025
Q2 		$6.06M Hold
1,450,638
– – 0.06% 63
2025
Q1 		$2.31M Hold
1,450,638
– – 0.03% 72
2024
Q4 		$4.11M Buy
1,450,638
+16,004
+1% +$66.9K 0.04% 74
2024
Q3 		$5.61M Buy
1,434,634
+934,634
+187% +$5.24M 0.06% 64
2024
Q2 		$4M Buy
+500,000
New +$5.93M 0.05% 72

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baker Bros. Advisors's SKYE Position: Q1 2026 in Review

Baker Bros. Advisors increased its Skye Bioscience (SKYE) stake by 8.6% in Q1 2026, buying an estimated $102K and bringing the position to 1,575,243 shares worth $968K. The position accounts for 0.01% of the portfolio, ranked #80.

Baker Bros. Advisors first reported a position in SKYE in Q2 2024 and has held it in 8 quarters since. The position peaked at $6.06M in Q2 2025. 39 funds tracked by Wall St. Rank hold SKYE as of Q1 2026.

  • Baker Bros. Advisors held 1,575,243 shares of Skye Bioscience worth $968K as of Q1 2026.
  • Baker Bros. Advisors bought 124,605 Skye Bioscience shares in Q1 2026, an estimated $102K.
  • Skye Bioscience made up 0.01% of Baker Bros. Advisors's portfolio in Q1 2026, its #80 holding.
  • Baker Bros. Advisors first reported a position in Skye Bioscience in Q2 2024 and has held it in 8 quarters since.
  • Baker Bros. Advisors's Skye Bioscience position peaked at $6.06M in Q2 2025.
  • 39 funds tracked by Wall St. Rank held Skye Bioscience as of Q1 2026.

Based on Baker Bros. Advisors's 13F filing for Q1 2026, filed 15 May 2026.